Onesource Specialty Pharma Limited (ONESOURCE)

Loading page…

Onesource Specialty Pharma Limited (ONESOURCE) · mywealthgrid

About

Onesource Specialty Pharma operates in the specialty pharmaceuticals segment of India's healthcare sector, with a market capitalization of ₹17,868 crore. The company generated revenues of ₹290–450 crore per quarter in recent periods, with operating margins averaging 21.4% but showing significant quarter-to-quarter volatility.

Face value: ₹1

Market cap

₹17,282 Cr

P/E

—

P/B

3.0×

Dividend yield

ROE

-1.3%

ROCE

0.6%

Debt / equity

0.22

OPM

21.4%

EPS (TTM)

₹-4.2

Book value

₹508.8

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Extreme earnings volatility: Dec 2025 saw net losses of ₹62–88 crore (OPM collapsed to 4–6%), followed by recovery to 25–28% OPM in Sep 2025 and Jun 2026, yet PE remains unavailable and ROE is negative at -1.26%

Stock performance disconnect: Down 16.81% over 1 year despite margin recovery in recent quarters, suggesting persistent market skepticism about earnings sustainability

Verify root cause of Dec 2025 loss: Operating profit fell from ~₹101 crore in Sep 2025 to ~₹13 crore in Dec 2025 in a single quarter — determine if one-time event, cyclical downturn, or structural issue

Verify revenue concentration and customer dependency: Quarterly revenues stable at ₹290–450 crore, but OPM varies 24 percentage points (from 28.34% to 4.42%) — check if tied to single customer or contract cycles

Generated analysis · source review pending

Growth drivers

Operating margin recovery and stabilization: Sep 2025 and Jun 2026 achieved 25–28% OPM after Dec 2025 loss, suggesting underlying business strength if sustainable

Financial flexibility for growth investments: D/E ratio of 0.22 provides capacity for debt-funded expansion or M&A if opportunities arise

Institutional investor inflows in latest quarter: FII holdings rose from 17.5% to 19.19% and DII from 20.61% to 23.38% — verify if this reflects improved forward guidance or investor reallocation

Consistent revenue base: ₹290–450 crore quarterly revenue range suggests stable customer relationships; verify if market share gains or new customer wins are driving any upside

Generated analysis · source review pending

413 historical price candles were omitted because the exchange source has not been verified.

₹1,508.0-4.8%1Y

Quick read

rule-based

Pros

+Healthy operating margin of 21.4%

Cons

−Low return on equity of -0.8% (3-yr avg)
−Weak interest coverage of 0.3×

Research score

Structured signal from quality, growth, valuation and momentum.

57/100

Business quality: 29
Growth: 100
Valuation: 41

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY SMALLCAP 50 NIFTY SMALLCAP 100 NIFTY SMALLCAP 250 NIFTY MIDSMALLCAP 400 NIFTY 500

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2024	Mar 2025	Mar 2026
	172	1,445	1,422
COGS	358	435	445
Gross profit	-186	1,010	977
	-98	543	673
	-88	467	304
OPM %	-51.3%	32.3%	21.4%
Depreciation	76	274	279
Interest	89	166	122
	-112	-94	5
Profit before tax	-366	-68	-92
Tax	—	-50	-18
Tax %	—	-73.5%	-19.8%
PAT	-366	-18	-74
PAT margin %	-212.7%	-1.2%	-5.2%
EPS (₹)	-88	-1.6	-6.4
EPS adjusted (₹)	—	-1.6	-6.4
Annual report	—	Annual report for Mar 2025	—

₹ Cr	Mar 2025	Mar 2026
Equity capital	11	11
Reserves	5,869	5,820
	772	1,276
	898	1,102
Total equity & liabilities	7,550	8,210
	6,118	6,017
CWIP	60	314
Investments	16	16
	1,357	1,863
Total assets	7,550	8,210

₹ Cr	Mar 2024	Mar 2025	Mar 2026
	-107	-22	9
	511	-201	-495
	-391	1,987	359
Net cash flow	13	1,765	-127
Free cash flow	—	-22	-561
CFO / Operating profit %	—	-4.6%	2.8%

Compounded sales growth

7 years: —
5 years: —
3 years: —
1 year: -2%

Return on equity

7 years: —
5 years: —
3 years: —
Last year: -1%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	-108.4%	69.9%	68.7%
EBITDA margin %	-51.3%	32.3%	21.4%
EBIT margin %	-95.7%	13.3%	1.8%
PAT margin %	-212.7%	-1.2%	-5.2%
Working capital
Receivable days	—	105	177
Inventory days	—	133	360
Payable days	—	147	307
NWC days	—	91	230
Leverage
Current ratio	—	0.98	0.99
Debt to EBITDA	—	1.65	4.2
Debt to equity	—	0.13	0.22
Interest coverage	-1.8	1.3	0.3
Asset turnover	—	0.19	0.17
Return ratios
Return on assets %	—	-0.2%	-0.9%
Return on capital employed %	—	3.3%	0.6%
Return on equity %	—	-0.3%	-1.3%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	37.77%	37.77%	34.25%	29.79%	29.77%	29.93%	30.48%	30.48%
	17.44%	17.44%	18.54%	18.69%	19.39%	19.24%	17.5%	19.19%
	12.56%	12.56%	18.04%	18.1%	18.49%	18.81%	20.61%	23.38%
Government	0%	0%	0%	0%	0%	0%	0%	0%
	32.23%	32.23%	29.17%	33.42%	32.35%	32.02%	31.41%	26.95%
No. of shareholders	—	—	—	—	87,416	84,595	79,460	77,899

Promoter holding down 7.29 percentage points since Sep 2024.

14 deals · 31 Jan 2025 – 21 Apr 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
21 Apr 2026	FIDELITY SECURITIES FUND: FIDELITY BLUE CHIP GROWTH FUND	Bulk	NSE	Buy	20,17,662	₹1,530.00	₹308.70 Cr
21 Apr 2026	NOVA GLOBAL OPPORTUNITIES FUND PCC - TOUCHSTONE	Bulk	NSE	Sell	10,57,902	₹1,530.00	₹161.86 Cr
21 Apr 2026	AUTHUM INVESTMENT & INFRASTRUCTURE LIMITED	Bulk	NSE	Sell	9,50,000	₹1,530.09	₹145.36 Cr
21 Apr 2026	AUTHUM INVESTMENT & INFRASTRUCTURE LIMITED	Bulk	NSE	Buy	1,72,668	₹1,556.69	₹26.88 Cr
17 Nov 2025	KARUNA BUSINESS SOLUTIONS LLP	Block	NSE	Buy	2,00,000	₹1,735.00	₹34.70 Cr
17 Nov 2025	AMANSA HOLDING PRIVATE LTD.	Block	NSE	Sell	2,00,000	₹1,735.00	₹34.70 Cr
15 May 2025	MEDELLA HOLDINGS PTE. LTD.	Bulk	BSE	Sell	8,84,210	₹1,568.04	₹138.65 Cr
31 Jan 2025	MEDELLA HOLDINGS PTE. LTD.	Bulk	NSE	Sell	19,41,748	₹1,552.90	₹301.53 Cr
31 Jan 2025	TENSHI PHARMACEUTICALS PRIVATE LIMITED	Bulk	NSE	Sell	19,41,747	₹1,545.03	₹300.01 Cr
31 Jan 2025	MEDELLA HOLDINGS PTE. LTD.	Bulk	NSE	Sell	19,41,747	₹1,548.54	₹300.69 Cr

1–10 of 14

1 / 2

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. Arun Kumar PillaiNon-Executive - Non Independent Director-Chairperson related to Promoter
Mr. Neeraj SharmaExecutive Director-MD
Ms. Debarati SenNon-Executive - Independent Director
Mr. Claudio AlbrechtNon-Executive - Independent Director
Mr. Vijay Paul KarwalNon-Executive - Independent Director
Mr. Bharat Dhirajlal ShahNon-Executive - Non Independent Director
Mr. Rashmi Harshadrai BarbhaiyaNon-Executive - Independent Director
Mr. Colin Michael BondNon-Executive - Independent Director
Trisha AlladaCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 13 fund houses

Held by these funds

10.29%

of the company's equity

All mutual funds

12.98%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

49 schemes · 13 fund houses

		Shares
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	37.22 L	565.38	2.8%	3.248%	-1 L
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	23.91 L	363.25	2.57%	2.087%	-0
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	10.9 L	165.58	3.23%	0.951%	-0
Focused FundNEW	360 ONE Mutual Fund	10.58 L	160.68	2.36%	0.923%	—
Small Cap Fund	Axis Mutual Fund	9.17 L	139.23	0.44%	0.8%	-0
Flexi Cap Fund	Axis Mutual Fund	6.01 L	91.34	0.66%	0.525%	-0
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	5.03 L	76.42	0.94%	0.439%	-0
Flexi CapNEW	360 ONE Mutual Fund	2.35 L	35.74	1.59%	0.205%	—

1–8 of 49

1 / 7

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Annual Report FY2025from bse Summary

Credit ratings

Investor Presentation and earnings call

Jul 2026Transcript AI SummaryPPTREC
May 2026Transcript AI SummaryPPTREC

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results24 Jul 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

24 announcementsExport CSV

11 Sept 2026, 5:02 pmCompany Update

General Update

General PDF

3 Sept 2026, 12:47 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

1 Sept 2026, 5:23 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

31 Aug 2026, 8:38 pmAGM/EGM

Notice Of The 19Th AGM Dated September 23, 2026

AGM PDF

31 Aug 2026, 8:34 pmOthers

Business Responsibility and Sustainability Reporting (BRSR)

Business Responsibility and Sustainability Reporting (BRSR) PDF

31 Aug 2026, 8:32 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

31 Aug 2026, 8:30 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

31 Aug 2026, 7:04 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

Date	Category	Subject	Filing
11 Sept 2026, 5:02 pm	Company Update General	General Update	PDF
3 Sept 2026, 12:47 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	PDF

Loading announcements…

Ratio	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	-108.4%	69.9%	68.7%
EBITDA margin %	-51.3%	32.3%	21.4%
EBIT margin %	-95.7%	13.3%	1.8%
PAT margin %	-212.7%	-1.2%	-5.2%
Working capital
Receivable days	—	105	177
Inventory days	—	133	360
Payable days	—	147	307
NWC days	—	91	230
Leverage
Current ratio	—	0.98	0.99
Debt to EBITDA	—	1.65	4.2
Debt to equity	—	0.13	0.22
Interest coverage	-1.8	1.3	0.3
Asset turnover	—	0.19	0.17
Return ratios
Return on assets %	—	-0.2%	-0.9%
Return on capital employed %	—	3.3%	0.6%
Return on equity %	—	-0.3%	-1.3%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Onesource Specialty Pharma Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Board meetings1

Announcements

Ratio timeline

Not in the F&O segment

Board meetings1

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

1

1